Intervacc AB (publ) has appointed Emma Hartman in the role of global product manager for Strangvac, a vaccine that is expected to become a game-changer in the fight against the global equine disease strangles. Emma Hartman has a DVM degree and most recently comes from MSD Animal Health, where she held the position of Nordic product manager for equine and ruminant products. Intervacc develops vaccines which aim to improve animal health. Earlier this year the company submitted its application for the granting of a Community marketing authorization for Strangvac to the European Medicines Agency (EMA). Equine strangles, caused by the bacterium Streptococcus equi, is the most common infectious disease of horses worldwide. The disease is characterized by the formation of abscesses in the head and neck of horses, which can literally strangle the horse to death. The strangles bacteria can also hide in apparently healthy recovered horses, called carriers, which enable it to persist and spread to new premises. Outbreaks of strangles can take a long time to resolve, requiring the implementation of many measures to limit the spread of infection and ultimately, eradicate the disease from an affected stable. Therefore, strangles is a priority animal health issue among the world's equine veterinarians.